Ziftomenib
Ziftomenib: A Promising New Treatment for NPM1-Mutated Acute Myeloid Leukemia
SG Tylor
Kura Oncology’s recent presentation at the European Hematology Association (EHA) 2023 conference highlighted the impressive clinical potential of ziftomenib in ...
Clinical Activity is Induced by Ziftomenib in NPM1-mutant R/R AML
SG Tylor
Source – Kura Oncology Phase I data from the KOMET-001 trial (NCT04067336) showed that treatment with Ziftomenib, a menin-MLL (KMT2A) ...
Kura makes a $100 million offer when AML is caused by a Menin inhibitor
SG Tylor
Source – Kura Oncology Safety problems had previously slowed down the development of Kura Oncology’s Menin inhibitor Ziftomenib for acute ...
Kura Oncology Unveils Promising Clinical Results of Ziftomenib, at the 2023 European Hematology Association (EHA) Congress
SG Tylor
Source – Kura Oncology Kura Oncology presented updated clinical data for its menin inhibitor, ziftomenib, at the 2023 European Hematology ...
